Scientifically protected skin

It provides relief for the skin and controls outbreaks in psoriasis and atopic dermatitis.

BIOIBERICA S.A., Pl. Francesc Macià, 7, 8ª planta. 08029 Barcelona (Spain). Tel. (+34) 93 490 49 08. www.bioiberica.com

TOPICAL AQUASORB and ORAL AQUASORB are complementary products that have greater therapeutic efficacy when used in combination.

Both products contain Chondroitin Sulfate. The administration of Chondroitin Sulfate by 2 routes helps to amplify and accelerate its effect.

Its combined administration provides the ingredients that have proven to be capable of recovering and maintaining the skin's balance with psoriasis and atopic dermatitis.

TOPICAL AQUASORBApply once or twice daily all over the body surface or to the specific areas to be treated.

ORAL AQUASORBTake 3 capsules a day, preferably in a single take and for three months. This period can be followed by a rest of 2 to 3 months, a�er which the regimen can be restarted and the same cycle followed.

FIRST COMPREHENSIVE TREATMENT FOR ATOPIC DERMATITIS AND PSORIASIS

Y30

550

0-0

715

BIOIBERICA, S.A. is a biotechnological company that specialises in the research, development and distribution of high biological and therapeutic value biomolecules that contribute to improving people's quality of life.

HEPARINThe most used anticoagulant and antithrombotic medicinal product in the world. 1 in 5 doses of heparin is by Bioiberica.

FUNCTIONAL LIPIDSBioiberica produces functional lipids with beneficial properties in different health areas: dermatological, cognitive and metabolic.

CHONDROITIN SULFATE, GLUCOSAMINE AND HYALURONIC ACIDOne of our priorities is to improve the quality of life of the 200 million-plus patients in the world that suffer from osteoarthritis, articular lesions and other musculoskeletal disorders.

Bioiberica specialises in the prevention, diagnosis and treatment of joint health.

This specialisation leads us to continuously investigate new applications in other therapeutic areas.

Formulations studied to leverage all the beneficial effects of its ingredients, which have proven their capacity to recover and maintain the balance of altered skin.

Reduction of Episodes

It provides relief for the skin and controls outbreaks in psoriasis and atopic dermatitis.

ErythemaPruritusDesquamationHyperkeratosisDryness

Clinical Improvement

TOPICALAQUASORB

ORALAQUASORB

2 products:

SCIENCE IN BIOMOLECULES APPLIED TO DERMATOLOGY

How does AQUASORB act in Psoriasis and Atopic Dermatitis?

· IT CONTROLS CLINICAL EPISODES· IT REDUCES THEIR FREQUENCY· IT MAKES IT POSSIBLE TO REDUCE DRUG DOSES

Ingredients with proven clinical efficacy

· 100% natural ingredients with a high safety profile

· No side effects and compatible with other treatments

· BIOIBERICA guarantees the maximum quality of its active ingredients

ACTION IN PSORIASIS AND ATOPIC DERMATITIS

· Highly-pure concentrated fatty acids.· Environmentally sustainable, endorsed by the Friends of the Sea Association

Chondroitin

Sulfate Sphingolipids (ceramide and sphingomyelin)

Hyaluronic Acid

Vitamins B7, B3 and B2

Om

ega

3

HYPERKERATOSIS DESQUAM

ATIO

N

DRYNESS PRURITUS

ERYT

HEM

A

PureMaxTM is a trade mark of Croda International Plc. England

BENEFITS Sphingolipids(ceramide and sphingomyelin)

Omega 3Vitamins

B7, B3 & B2Hyaluronic

Acid

Reduces skin inflammation

Stimulates endogenoussynthesis of ceramides

Improves skinhydration

Reduces skinirritation

Improves clinicaloutcome

Controls pruritus

Chondroitin Sulfate

NEW INGREDIENTS IN DERMATOLOGY

It reduces the signs of psoriasis (n=129)

The administration of CS for 3 months delivers a statistically significant reduction in the signs of psoriasis.

Reduction in the intensity of psoriasis a�er 3 months of treatment.

Days00

5

10

15

20

25

30

35

30 60 90

Patie

nts w

ith p

lant

ar p

soria

sis (%

)

Placebo Chondrotin sulfate

Möller I. et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study. Osteoarthritis Cartilage. 2010;18 Suppl 1:S32-40.

Clinical and histological improvement in psoriatic plaques in 91% of the casesSecond clinical case performed with 11 patients with osteoarthritis and psoriasis concomitantly

Epidermis thickness before treatment.

54% reduction in the total thickness of the epidermis treated for two months with chondroitin sulfate.

Vergés J. et al. Clinical and histopathological improvement of psoriasis with oral chondroitin sulfate: a serendipitous finding. Dermatol Online J. 2005 Mar 1;11(1):31.

The administration of CS B BIOACTIVE achieves an outstanding clinical and histological clinical benefit in psoriatic lesionsFirst clinical case carried out with 3 patients with osteoarthritis and psoriasis concomitantly

Vergés J. et al. Mejoría clínica y anatomopatológica de la psoriasis en pacientes con artrosis tratados con condroitín sulfato: descripción de 3 casos. Med Clin 2004; 123(19):739-742.

Before treatment A�er treatment Before treatment A�er treatment

74% reduction in keratinocytes (Ki-67) cell proliferation rate in a 57-year-old patient treated with 800mg/day of

chondroitin sulfate for 2 months.

54% reduction in total epidermis thickness in a 67-year-old patient treated for 2 months with 800mg/day of chondroitin sulfate.

SCIENCE IN PSORIASIS AND ATOPIC DERMATITIS

It reduces skin inflammation

· Psoriasis and atopic dermatitis have an important inflammatory component.· In patients with psoriasis, there is a deregulation of NF-kB that leads to a pro-inflammatory condition.· CS reduces the translocation of NF-kB and consequently reduces skin inflammation.· CS presents an excellent safety profile

Souich P. et al. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cel Mol Med 2009; 13(8A): 1451-1463

p50 p65p38 MAPK

Erk 1/2H2O2/O2

IL-1R

CSCS

CS

S276S536

p50 p65 mARN

PROTEOLYTIC ENZYMES

PRO-INFLAMMATORY ENZYMES

PRO-INFLAMMATORYCYTOKINES

MMP-3MMP-9MMP-13Catepsina B

PLA2, COX-2NOS-2

TNF-αIL-1ß

Mechanism of action of Chondroitin Sulfate

Chondroitin Sulfate

Reduces skin inflammation

Omega 3 (EPA and DHA)It stimulates the endogenous synthesis of ceramides, improving the skin's lipid structure and composition.

Skin moisturisation and elasticity

Hyaluronic Acid

· The oral administration of omega-3 fatty acids complements the topical treatment of psoriasis, significantly contributing to a reduction in pruritus, erythema and desquamation in the affected areas. BIOSFEEN contains sphingomyelin, which has a

dose-dependent inhibition effect on the synthesis of PGE2 in an in vitro keratinocyte model.

In atopic dermatitis, there is a reduction in the content of skin ceramides that compromises the epidermis's barrier function.

The application of the BIOSFEEN sphingolipid extract stimulates the endogenous synthesis of ceramides.

Improvement in the skin's lipid structure and composition.

Hyaluronic acid is a glycosaminoglycan present in the epidermis, and one of the main components of the extracellular matrix. It has a high water retention capacity and has been proven to play a central role in skin moisturisation and elasticity.

Price RD. et al. Hyaluronic acid: the scientific and clinical evidence. J Plast Reconstr Aesthet Surg. 2007;60 (10):1110-1119.

Mason F. Skin hydration and hyaluronic acid. Ann Dermatol Venereol 2010;137 Suppl 1:S23-S25.

· Supplementation with DHA led to an increase in omega-3 plasma concentration, resulting in a clinical improvement of atopic eczema determined by a reduction in the SCORAD index.

Keratinocyte culture

Control Sphingomyelin

Con

cent

ratio

n of

PG

E 2

SCIENCE IN PSORIASIS AND ATOPIC DERMATITIS

Cerrato S et al. Effects of sphingolipid extracts and glycosaminoglycans on morphological structure and lipid content in an in vitro canine skin model. Veterinary Dermatology 2015; 26:299.

Internal Data

Koch C et al. Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, controlled trial. Br J Dermatol 2008;158(4):786-792.

Sphingolipids

BjØrneboe A et al. Effect of n-3 fatty acid supplement to patients with atopic dermatitits. J Intern Med Suppl. 1989;731:233-236.

Mayser et al. A double-blind, randomized, placebo-controlled trial of n=3 versus n=6 fatty acid-based lipid infusion in atopic dermatitis. JPEN J Parenter Enteral Nutr. 2002;26(3):151-158.

75% reduction in inflammation

Study to evaluate Aquasorb's efficacy in patients with dermal alterationsPrincipal investigator: Montse Pérez MD (Clínica Moragas)

· The improvement in global clinical index is 78%.

· In 80% of the patients, there is an improvement in the degree of desquamation, erythema, pruritus, hyperkeratosis and fissures and/or cracks.

· The improvement in global clinical index is 78%.

· Pruritus and erythema are significantly reduced in all patients

0%10%20%30%40%50%60%70%80%90%

100%

Initial

Degree ofdesquamatión

Degree oferythema

Degree ofpruritus

Degree ofhyperkeratosis

Degree of fissures/cracks

Final Initial Final Initial Final Initial Final Initial Final

Initial

Degree ofdesquamatión

Degree oferythema

Degree ofpruritus

Degree ofhyperkeratosis

Degree of fissures/cracks

Final Initial Final Initial Final Initial Final Initial Final

Very severe

Severe

Moderate

Mild

Null

Very severe

Severe

Moderate

Mild

Null

0%10%20%30%40%50%60%70%80%90%

100%

EFFICACY IN PSORIASIS AND ATOPIC DERMATITIS

PATIENTS WITH PSORIASIS

PATIENTS WITH ATOPIC DERMATITIS

PSORIASIS ATOPIC DERMATITIS

Degree of hyperkeratosis (0-4)

Degree of fissures/cracks (0-4)

Degree of pruritus (0-4)

Degree of erythema (0-4)

Degree of desquamation (0-4)

Baseline Mass Index (0-20)

Body Mass Index

Age

Sex (Men/Women) (%)

3

2

2

2

1

50±5,2

26±1,8

10±0,5

50/50

DesquamationErythemaPruritusHyperkeratosisFissures/Cracks

Effect of AQUASORB on the clinical symptoms of dermal alterations using the following parameters in 18 patients with psoriasis or atopic dermatitis:

It provides relief for the skin and controls outbreaks in psoriasis and atopic dermatitis.

2

2

3

1

1

25±1,3

47±5,3

8±0,3

25/75